Navigation Links
Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
Date:9/22/2007

by calling 1-800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products, including the results of any clinical programs with respect to TREANDA or the timing or acceptance of any current or future filings for regulatory approval of TREANDA or other Cephalon Oncology compounds; interpretation of clinical results, particularly with respect to the TREANDA clinical trials; manufacturing development and capabilities; market prospects for its products; sales and earnings guidance; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Provigil Patent Extension Accorded To Cephalon
2. Novartis files application with FDA for Zometa
3. Morepan to file new drug applications with the USFDA
4. Mini motor for micromedical applications
5. Perfusion bioreactor could enhance stem cell research and application in the future
6. Prostate Cancer Can Be Treated By Application Of LASER Technology
7. Varied Applications of Adult Stem Cells to Treat Host of Disorders in Human
8. Venus Remedies Files 5th International Patent Application
9. NICE supports application of advanced biological therapies as treatment option for acute psoriasis
10. Roche puts in an Application to Use Herceptin for Treatment in Her-2 positive breast cancer
11. New Drug Application Submitted for Investigational Antibiotic Doripenem
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... ... September 03, 2015 , ... ... cost increases for fully insured employer-sponsored health insurance plans, more employers are moving ... according to data released from the 2014 United Benefit Advisors (UBA) Health Plan ...
(Date:9/3/2015)... ... September 03, 2015 , ... DiabetesSisters Welcomes ... to announce the additional of Carol Wysham, MD, to their esteemed Board of ... Karczmarczyk, Donna Rice, David Warren, Matt Stella, Tricia Cedotal, Andrea Thomas, Wanda Nicholson ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... endpoint data collection, cloud analytics and workflow solutions today announced the complete ... Portugal, September 22-24, 2015. The esteemed faculty of worldwide pharmaceutical and industry ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... responsibility concierges; simplifying responsibilities which can impact the delicate life balance between work ... situation might be.” - Jeffrey R. Leaptrott, CEO , A LifeMinder Plus® Emergency ...
(Date:9/3/2015)... NJ (PRWEB) , ... September 03, 2015 , ... ... today that AvePoint Perimeter Service Pack (SP) 4 – AvePoint’s solution for ... been named a “KMWorld 2015 Trend-Setting Product”. This is the fifth consecutive ...
Breaking Medicine News(10 mins):Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4Health News:Carol H. Wysham, MD, Joins DiabetesSisters Board of Directors 2Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 2Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 3Health News:LifeMinder Plus® Announces Emergency Care Document Set Giveaway for America 2Health News:LifeMinder Plus® Announces Emergency Care Document Set Giveaway for America 3Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 2Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 3Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 4
... ... can help to prevent cavities. , ... Delray Beach, FL (PRWEB) July 8, 2009 -- Cavities are a persistent problem for ... to prevent them, according to Delray Beach, Florida-based dentist Dr. Craig Spodak, is to use ...
... 7 iMedX Inc., a leading healthcare software and services ... With this acquisition, iMedX expands its reach into the hospital ... companies in the United States. , , Based just ... systems across the country, utilizing a labor force of over ...
... OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a leader in ... today that its Board of Directors has retained Emerging Growth ... in evaluating strategic alternatives with a focus on acquisitions that ... believe that the scope of our product offerings and broad ...
... engineering David Bruce will participate in a multi-university Energy ... the U.S. Department of Energy. The Center for Atomic-Level ... new catalysts for the production of clean fuels and ... of CALCD, combined with those of 45 other new ...
... (Nasdaq: XTNT ) today announced that it has postponed ... at 9:00 a.m. Pacific Time on Thursday, July 9, 2009. ... August 3, 2009. , , On May 15, ... approved a Plan of Complete Liquidation and Dissolution of the Company ...
... (ZixCorp(R)), (Nasdaq: ZIXI ), the leader in hosted ... corporate update by its chief executive officer, Rick Spurr. , ... ZixCorp and we are on target to report within the ... are that we should meet our revenue guidance of $7.3 ...
Cached Medicine News:Health News:South Florida Dentist Dr. Craig Spodak Recommends Artificial Sweetener Xylitol to Help Prevent Cavities 2Health News:iMedX Announces Acquisition of Medware Inc. 2Health News:OmniComm Systems, Inc. Retains Emerging Growth Equities, Ltd., as its Strategic Financial Advisor 2Health News:OmniComm Systems, Inc. Retains Emerging Growth Equities, Ltd., as its Strategic Financial Advisor 3Health News:DOE funds Clemson University clean energy research 2Health News:XTENT, Inc. Announces That It Has Postponed the Special Meeting of Its Stockholders 2Health News:Zix Corporation CEO Provides Corporate Update for Second Quarter 2009 2Health News:Zix Corporation CEO Provides Corporate Update for Second Quarter 2009 3Health News:Zix Corporation CEO Provides Corporate Update for Second Quarter 2009 4
(Date:9/3/2015)... and REHOVOT, Israel, Sept. 3, 2015 OticPharma, ... developing innovative therapies for ear, nose, and throat (ENT) ... Newport Gateway office complex to be the location of ... move by end of September and will have office ... Headquarters: OticPharma, Inc. 19900 MacArthur Blvd., Suite ...
(Date:9/2/2015)... NEW YORK , Sept. 2, 2015  The ... the future market of breast cancer drugs on the ... Breast cancer usually originates from the inner lining of ... This is a malignant type of tumor that can ... type of cancer which starts in lobules is referred ...
(Date:9/2/2015)... LONDON , Sept. 2, 2015 ... Forecasts Summary Advanced dressings have steadily ... treatment of a variety of wound indications, such ... fluid management, infection control, and physical protection become ... a greater role in standard therapy. This ...
Breaking Medicine Technology:OticPharma Establishes U.S. Headquarters in Orange County, California 2Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3Advanced Wound Dressings - 5EU Analysis and Market Forecasts 2
... of Vermillion, Inc. (NASDAQ: VRML ), a leading ... successor to Gail S. Page, president and CEO. The board ... the search by September 2012. James S. Burns, ... led the divestiture of the company,s original research tools business, ...
...  InfuSystem Holdings, Inc. (NYSE MKT:  INFU), the leading national ... healthcare industry, today announced that it will release results ... 2012 following the market close.  The ... May 22, 2012 at 9:00 a.m. Eastern Time.  To ...
Cached Medicine Technology:Vermillion Announces CEO Succession Plan 2Vermillion Announces CEO Succession Plan 3Vermillion Announces CEO Succession Plan 4
9 mm wide tip. 35 mm from angle to tip....
Double-ended. 5 mm x 7 mm tips. Designated most popular model or size....
Double-ended. 3 mm x 5 mm curette end and 3 mm spatula end....
Double-ended. Semi sharp. Curved 3 mm tips. Angled right and left....
Medicine Products: